← All Apollomics INC filings

Apollomics INC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
APLM
Apollomics INC
20-F: Apollomics Faces Going Concern Doubt Amid Program Cuts, Losses
Apollomics Inc. reported significant losses and a negative equity position for 2025, raising substantial doubt about its ability to continue as a going concern, following multiple drug program terminations and a deferred key U.S. regulatory filing.
NASDAQ
APLM
Apollomics INC
20-F: Apollomics Inc. Files 20-F Annual Report, Cites Liquidity Concerns Despite Pipeline Progress
Apollomics Inc.'s 20-F filing reveals ongoing net losses and a need for additional capital, despite advancements in its oncology pipeline and a recent licensing agreement.
NASDAQ
APLM
Apollomics INC
20-F: Apollomics Extends Office Lease, Modifies Terms in Foster City
Apollomics Inc. amends its office lease in Foster City, California, extending the term while reducing the leased space.